Major adverse cardiac events and drug-coated balloon size in coronary interventions

David Naguib#, Betül Knoop#, Lisa Dannenberg, Eva Liebsch, Martin Pöhl, Carolin Helten, Athena Assadi-Schmidt, Malte Kelm, Tobias Zeus, Amin Polzin

Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Düsseldorf; Düsseldorf-Germany

Abstract

Objective: In-stent restenosis (ISR) is a feared complication after coronary stent implantation. Drug-coated balloon (DCB) is being promoted as a treatment option for ISR. However, the benefit-risk ratio of DCB length has not been investigated. Longer DCBs release more anti-proliferative drug to the vessel wall; however, they are associated with a higher lesion length and vessel injury. Hypothesis: DCB length is associated with clinical outcome.

Methods: We analyzed 286 consecutive Pantera Lux (Biotronik, active component Paclitaxel) DCB-treated patients between April 2009 and June 2012. Of them, 176 patients were treated using a 15-mm DCB and 109 were treated using a 20-mm DCB. Baseline characteristics and major adverse cardiac events (MACE; death, myocardial infarction, and target lesion revascularization) during initial hospital stay and a 2-year follow-up period were obtained.

Results: Patients characteristics such as cardiovascular risk factors, prior diseases, co-medication, clinical presentation, target vessel, and left ventricular function did not differ between the groups. MACE during hospital course was similar [1.7% vs. 2.8%, relative risk (RR) 1.6, 95% confidence interval (CI) 0.3-7.9, p=0.554]. Likewise, at 2-year follow-up, MACE did not differ between the groups (23.2% vs. 27.5%, RR 1.2, 95% CI 0.6-1.5, p=0.408).

Conclusion: DCB length was not associated with clinical outcome during a 2-year follow-up period. (Anatol J Cardiol 2018; 19: 382-7)

Keywords: drug-coated balloon, drug-eluting stent, MACE, paclitaxel

Introduction

The treatment of coronary artery disease was revolutionized by balloon angioplasty and stent implantation. However, common complications observed after coronary stent implantation are stent thrombosis, myocardial infarction (MI), and repeated need for revascularization (1). Stent thrombosis is particularly associated with a substantially increased (up to 30%) risk of death (2). Among other factors, a strong independent risk factor for major adverse cardiac events (MACE) is stent length. Stent length is associated with stent thrombosis, death, MI, and target lesion revascularization (TLR) (3-5). Besides acute adverse events, restenosis due to neointimal growth is still a major concern after stent implantation (6). After 5 years, 10% of drug-eluting stent-treated patients and 20%-30% of bare-metal stent treated patients experience in-stent restenosis (ISR) with need for repeat revascularization (7, 8). Drug-coated balloon (DCB) angioplasty is a promising treatment for ISR (8-11). DCB are semi-compliant and covered with an anti-proliferating drug; during angioplasty, they release this active agent into the vessel wall (12). However, it is not known whether DCB length is associated with clinical outcome. Longer DCBs are used in larger lesions as they release more anti-proliferative drug into the vessel wall; however, they cause more vessel injury. In this study, we conducted a hypothesis-generating pilot analysis of the Düsseldorf DCB registry. We aimed to associate DCB length and clinical outcome during hospital course and a 2-year follow-up.

Methods

Study design, patient population, follow-up

Data of 286 paclitaxel DCB (Pantera Lux, BIOTRONIK, SE & Co.KG, Berlin, Germany)-treated patients of the Düsseldorf DCB registry were analyzed in a retrospective manner. Of all the patients, 176 (61.8%) were treated using a 15-mm DCB and 109 (38.2%)
were treated using a 20-mm Pantera Lux DCB between April 2009 and June 2012. Quantitative coronary stenosis assessment (QCA) was not performed, and the lesion length was estimated regarding the pre-dilatation parameters by an interventionalist. DCB inflation was performed, and inflation duration and pressure were registered and compared between the groups.

Follow-up was conducted during ambulatory care at the Cardiology Department of the Heinrich-Heine-University Clinic Düsseldorf (Düsseldorf, Germany). The analysis was approved by the Ethics Committee of the Heinrich-Heine-University Düsseldorf (Düsseldorf, Germany).

**Study endpoints**

The incidences of TLR, MI, and all-cause death were investigated during hospital course and at 2-year follow-up appointment. Signs of ischemia, elevation of cardiac enzyme levels, and angiographically proven culprit lesion defined MI. Repeated revascularization of the DCB target lesion without meeting MI criteria was defined as TLR.

**Statistical analysis**

Statistical analysis was performed using IBM SPSS©-Software (New York, USA) and GraphPad Prism statistical software (GraphPad Software Inc, San Diego). Calculation of relative risk (RR) with 95% confidence interval (CI) was done according to Altman (13). Hazard ratios (HRs) with 95% CI and log-rank test were used in MACE analysis. Normal distribution was tested using histograms, QQ-plots, and Kolmogorov-Smirnov test. Gaussian-distributed continuous variables were analyzed using t-test. Non-normally distributed variables were assessed using Mann-Whitney U test. Categorical variables were analyzed using Fisher’s exact and \( \chi^2 \) tests as applicable. All tests were two tailed, and \( p<0.05 \) was considered significant. This was a hypothesis-generating explorative analysis; therefore, no power calculation was conducted.

**Results**

**Baseline characteristics**

Mean age of the study population was 73±10 years; 121 (68.4%) patients were male. Gender and body mass index (27±5 vs. 28±5; \( p=0.368 \)) did not differ between the groups. Likewise, there were no significant differences between the groups regarding cardiovascular risk factors, medical history, clinical presentation, left ventricular function, or medication at discharge. Detailed baseline characteristics are illustrated in Tables 1 and 2 and Supplemental 1.

| Table 1. Patients characteristics |
|----------------------------------|
| **Characteristics**              |
| **15 mm**                        |
| **n=177**                        |
| **20 mm**                        |
| **n=109**                        |
| **P-value**                      |
| **15 mm**                        |
| **20 mm**                        |
| **P-value**                      |
| Characteristics                  |
| Age, years (mean ± SD)           |
| 73±10                            |
| 73±10                            |
| 0.670                            |
| Male gender, no. (%)             |
| 121 (68.44%)                     |
| 83 (76.1%)                       |
| 0.121                            |
| Height, cm (mean ± SD)           |
| 174±9                            |
| 171±9                            |
| 0.622                            |
| Weight, kg (mean ± SD)           |
| 82±18                            |
| 81±17                            |
| 0.279                            |
| Body mass index, kg/m\(^2\) (mean ± SD) |
| 27±5                             |
| 28±5                             |
| 0.368                            |
| Cardiovascular risk factors, no. (%) |
| Hypertension                     |
| 177 (100%)                       |
| 109 (100%)                       |
| >0.999                           |
| Hypercholesterolemia             |
| 168 (95%)                        |
| 105 (96%)                        |
| 0.771                            |
| Diabetes mellitus                |
| 58 (33%)                         |
| 44 (40%)                         |
| 0.212                            |
| Current smokers                  |
| 58 (33%)                         |
| 28 (26%)                         |
| 0.225                            |
| Obesity (BMI >30 kg/m\(^2\))     |
| 39 (22%)                         |
| 26 (24%)                         |
| 0.771                            |
| Medical history, no. (%)         |
| Prior myocardial infarction      |
| 74 (42%)                         |
| 50 (46%)                         |
| 0.536                            |
| Prior CABG                       |
| 30 (17%)                         |
| 21 (19%)                         |
| 0.642                            |
| Prior stroke                     |
| 10 (6%)                          |
| 7 (6%)                           |
| 0.801                            |
| Chronic kidney disease           |
| 52 (29%)                         |
| 30 (28%)                         |
| 0.788                            |
| Dialysis                         |
| 5 (3%)                           |
| 2 (2%)                           |
| 0.707                            |

*P-value of Fisher’s exact and \( \chi^2 \) tests in categorical variables and t-test in continuous variables; BMI - body mass index; CABG - coronary artery bypass surgery
DCB intervention

DCB procedure was successfully performed in 278 (97.5%) cases. Mean inflation duration was 50.2±12 s, and mean inflation pressure was 10.53±3.7 atm. There were no differences regarding inflation pressure and duration between the groups. Vessel dissection was seen in 21 (7.4%) patients. Overall, the left anterior descending artery was the predominant target vessel (42% vs. 34%, p=0.320). BMS-ISR was the most common cause for DCB intervention (46% vs. 51%, p=0.472). Bifurcation lesions were significantly more often treated using a 15-mm DCB (15% vs. 2%, p<0.001). Vessel dissection incidence, inflation pressure, inflation duration, and vessel diameter was similar in both groups. An additional stent implantation during DCB procedure was seen in 48 (16.8%) cases, and it did not differ between the groups. Procedure-related data has been presented in Table 3 and Supplemental 1. All types of lesions were included (including saphenous graft lesions, n=22). There were no re-conducted DCB interventions after initial DCB interventions in this cohort (Supplemental 2).

Study endpoints

During hospital course, the occurrence of MACE was similar between 15-mm and 20-mm DCB groups [3 patients (1.7%) vs. 3

Table 2. Clinical presentation and systolic left ventricular function

|                | 15 mm (n=177) | 20 mm (n=109) | P-value* |
|----------------|---------------|---------------|----------|
| Presentation, no. (%) |               |               |          |
| ST-elevation myocardial infarction | 8 (5%)        | 2 (2%)        | 0.331    |
| Non-ST-elevation myocardial infarction | 27 (15%)      | 21 (19%)      | 0.423    |
| Instable angina pectoris | 62 (35%)      | 35 (32%)      | 0.699    |
| Stable coronary artery disease | 70 (40%)      | 35 (32%)      | 0.208    |
| CCS-Stage |               |               | 0.944    |
| CCS 0     | 60 (34%)      | 38 (35%)      |          |
| CCS I    | 18 (10%)      | 11 (10%)      |          |
| CCS II   | 35 (20%)      | 16 (15%)      |          |
| CCS III  | 25 (14%)      | 12 (11%)      |          |
| CCS IV   | 39 (22%)      | 32 (29%)      |          |
| NYHA-Stage |               |               | 0.123    |
| NYHA I   | 77 (44%)      | 50 (46%)      |          |
| NYHA II  | 53 (30%)      | 38 (35%)      |          |
| NYHA III | 32 (18%)      | 19 (17%)      |          |
| NYHA IV  | 15 (8%)       | 2 (2%)        |          |
| Left ventricular function, no (%) |               |               |          |
| Normal    | 95 (54%)      | 60 (55%)      | 0.902    |
| Mildly decreased | 37 (21%) | 28 (26%) | 0.377 |
| Moderately decreased | 25 (14%) | 10 (9%) | 0.260 |
| Severely decreased | 20 (11%) | 11 (11%) | 0.851 |

*p-value of Fisher’s exact and x² tests; CAD - coronary artery disease; CCS - Canadian Cardiovascular Society; NYHA - New York Heart Association

Figure 1. Drug-coated balloon length and MACE. Drug-coated balloon length in coronary intervention was not associated with the incidence of major adverse cardiac events (MACE; death, myocardial infarction, and target lesion revascularization) during hospital stay (a) and at 2-year follow-up (b) patients (2.8%, p=0.554). Likewise, at 2-year follow-up, MACE did not significantly differ between the groups (41 patients (23.2%) vs. 30 (27.5%), p=0.408; Table 4, Fig. 1). During follow-up period, one patient died. MACE was predominantly caused by TLR (21.7% of 15-mm DCB-treated patients vs. 22% of 20-mm DCB-treated patients, p=0.925). MI occurred numerically more frequently in 20-mm DCB-treated patients (12.8% vs. 7.3%, p=0.294; Table 4).
Discussion

The major finding of this pilot analysis was that DCB length is not associated with MACE.

By now, it is well known that coronary stent length is a predictor for outcome for ISR (3-5). Enhanced stent length is associated with more vascular injury as well as increased platelet activation and higher risk of stent thrombosis (14). At the moment, either a DCB angioplasty or a percutaneous coronary intervention with everolimus-eluting stents (that gives best angiographic and clinical

---

Supplemental 1. Medication

| Medication – no. (%) | 15 mm n=177 | 20 mm n=109 | P-value* |
|----------------------|-------------|-------------|---------|
| Aspirin              | 161 (91%)   | 104 (95%)   | 0.24    |
| P2Y12 inhibitor      | 172 (97%)   | 108 (99%)   | 0.41    |
| Oral anticoagulation | 41 (23%)    | 16 (15%)    | 0.09    |
| ACE- /AT-II-receptor- inhibitor | 153 (86%) | 95 (87%) | 0.86    |
| Beta- blocker        | 147 (83%)   | 97 (89%)    | 0.23    |
| Calcium- channel inhibitor | 46 (26%) | 28 (26%) | 0.95    |
| Aldosterone antagonist | 20 (11%)  | 12 (11%)    | 0.94    |
| Cardiac glycoside    | 15 (8%)     | 5 (5%)      | 0.24    |
| Proton-pump inhibitor | 59 (33%)  | 36 (33%)    | 0.96    |
| Statin               | 147 (83%)   | 98 (90%)    | 0.12    |
| Oral antidiabetic    | 35 (20%)    | 19 (17%)    | 0.64    |
| Insulin              | 14 (8%)     | 12 (11%)    | 0.4     |
| Allopurinol          | 32 (18%)    | 22 (20%)    | 0.76    |
| NSAID                | 2 (1%)      | 1 (1%)      | 0.86    |
| Dipyrone             | 3 (2%)      | 4 (4%)      | 0.43    |
| Morphine             | 10 (6%)     | 3 (3%)      | 0.38    |

*P-value of Fischer’s exact test and Chi-squared test; ACE – angiotensin-converting-enzyme; AT – angiotensin; NSAID – non steroidal anti inflammatory drug

Supplemental 2. Target vessel and drug-coated balloon indication

| Target vessel – no. (%) | 15 mm n=177 | 20 mm n=109 | P-value* |
|-------------------------|-------------|-------------|---------|
| Left anterior descending| 75 (42%)    | 38 (34%)    | 0.320   |
| Left circumflex         | 36 (20%)    | 28 (26%)    | 0.311   |
| Right coronary artery   | 49 (27%)    | 35 (32%)    | 0.425   |
| Venous bypass graft     | 15 (8%)     | 7 (6%)      | 0.649   |
| Ramus intermedius       | 2 (1%)      | 1 (1%)      | 0.863   |
| Indication – no. (%)    | 15 mm n=177 | 20 mm n=109 | P-value* |
| BMS ISR                 | 82 (46%)    | 56 (51%)    | 0.472   |
| DES ISR                 | 43 (24%)    | 30 (27%)    | 0.570   |
| Bifurcation             | 26 (15%)    | 2 (2%)      | <0.001  |
| De-novo lesion          | 19 (11%)    | 16 (15%)    | 0.362   |
| Others                  | 7 (4%)      | 5 (5%)      | 0.774   |

*P-value of Fischer’s exact test and Chi-squared test; BMS – bare metal stent; DES – drug eluting stent
results) is recommended in ISR (8). DCB angioplasty is particularly very promising in ISR as no additional stent layer is needed. In a previous analysis, we demonstrated that Pantera Lux DCBs were superior to Sequent Please DCBs in prevention of adverse events (15). A tendency towards a higher incidence of MACE in patients treated with longer DCBs was observed. Therefore, we aimed to systematically investigate this issue in the present analysis. Contrary to our initial expectation, the present study suggests that DCB length does not impact the clinical outcome. Although patients undergoing treatment using 20-mm DCB might have had longer lesions, their outcome was not impaired. Hypothetically, a higher release of paclitaxel could counterbalance the more extensive stage of coronary artery disease represented by longer lesions.

However, this pilot study had several limitations. The number of patients in this pilot analysis was limited. It was a non-randomized, single-center analysis; however, it reflected a real-world population. Moreover, due to the retrospective design of this analysis, procedural data are limited; especially, QCA was not routinely conducted. Although QCA is a known standard procedure, there is also some evidence for an inter-core lab variability, especially concerning bifurcation stenosis (16). Moreover, it has been shown that evaluation of lesions using QCA is not superior to assessment by the interventional cardiologist (17). Therefore, lesion length is estimated regarding the pre-dilatation parameters by the interventionalist at our center. Furthermore, several patients presented with initial stent implantation which was conducted in external

### Table 3. Drug-coated balloon procedure

|                          | 15 mm (n=177) | 20 mm (n=109) | P-value* |
|--------------------------|---------------|---------------|----------|
| **Balloon (mean±SD)**    |               |               |          |
| Diameter (mm)            | 3.04±0.6      | 3.06±0.7      | 0.783    |
| Inflation pressure (atm) | 10.15±3.2     | 10.90±4.1     | 0.087    |
| Inflation duration (s)   | 49.83±12      | 50.56±12      | 0.621    |
| **Vessel dissection, no. (%)** | 13 (7%) | 7 (6%) | 0.820 |
| **Combinations, no (%)** |               |               |          |
| DCB only                 | 145 (82%)     | 93 (85%)      | 0.508    |
| DCB+Bare metal stent     | 16 (9%)       | 8 (7%)        | 0.659    |
| DCB+Drug eluting stent   | 16 (9%)       | 8 (7%)        | 0.660    |
| **Procedural result, no. (%)** |           |               |          |
| Angiographic success     | 173 (98%)     | 105 (96%)     | 0.481    |
| No success               | 4 (2%)        | 4 (4%)        | 0.480    |

*P-value of Fischer’s exact and χ² tests in categorical variables and t-test in continuous variables; DCB - drug-coated balloon

### Table 4. Occurrence of MACE

|                          | All (n=286) | 15 mm (n=177) | 20 mm (n=109) | P-value |
|--------------------------|------------|---------------|---------------|--------|
| **MACE during hospital course** |            |               |               |        |
| Death                    | 6 (2.1%)   | 3 (1.7%)      | 3 (2.8%)      | 0.554  |
| Myocardial infarction    | 2 (0.7%)   | 1 (0.6%)      | 1 (0.9%)      | 0.931  |
| TLR                      | 3 (1.1%)   | 2 (1.1%)      | 1 (0.9%)      | 0.341  |
| **MACE at 2-year follow-up** | 71 (24.8%) | 41 (23.2%)    | 30 (27.5%)    | 0.408  |
| Death                    | 1 (0.3%)   | 0 (0.0%)      | 1 (0.9%)      | 0.203  |
| Myocardial infarction    | 25 (8.7%)  | 13 (7.3%)     | 14 (12.8%)    | 0.294  |
| TLR                      | 62 (21.7%) | 38 (21.4%)    | 24 (22.0%)    | 0.925  |

*P-value of χ² test in categorical variables; MACE - major adverse cardiac events; TLR - target lesion revascularization
Drug-coated balloon length and major adverse cardiac events

Naguib et al.

Anatol J Cardiol 2018; 19: 382-7
DOI:10.14744/AnatolJCardiol.2018.67864

hospitals; thus, information about stent length was not available for every case. Consequently, standard ratios like stent to balloon length ratio and lesion to balloon length ratio are missing in this study. Additionally, no intravascular ultrasound or optical coherence tomography was performed. Therefore, we were unable to evaluate angiographic mismatch. Despite these important limitations regarding procedural details, the aim of this pilot study was to focus on the evaluation of DCB length as predictor of clinical outcome. We concluded that DCB length was not associated with clinical outcome.

The results of this study might lead to the hypothesis that a moderate oversizing of DCB does not affect long-term clinical outcome. However, despite the fact that there were no significant differences in clinical outcome, MACE were numerically higher in 20-mm DCB-treated patients. Additionally, 15-mm DCBs were more frequently used in bifurcation stenosis cases. Besides that, patients’ characteristics, prior disease, clinical presentation, and procedural details did not significantly differ between the groups. However, even non-significant differences might have biased the results. The number of patients was too small to allow reasonable multivariate analyses. In this rapidly evolving field owing to advanced technology, the findings of our study have to be confirmed in large-scale, randomized clinical trials and meta-analyses.

Conclusion

DCB length was not associated with clinical outcome. Rates of MACE did not differ between the 15-mm and 20-mm DCB-treated patients during hospital stay and 2-year follow-up. These findings have to be reconfirmed in clinical trials and meta-analyses.

Funding: Part of this work was supported by the Forschungskommission of the Medical Faculty of the Heinrich Heine University (No. 16-2014 to A.P.; No. 46-2016 to L.D.).

Conflict of interest: None declared.

Peer-review: Externally peer-reviewed.

Authorship contributions: Concept – TZ, A.P.; Design – TZ, A.P.; Supervision – M.K., TZ, A.P.; Fundings – LD, A.P.; Materials – D.N., B.K., LD., E.L., M.P., A.A.; Data collection &/or processing – D.N., B.K., E.L., M.P., C.H., A.A.; Analysis &/or interpretation – D.N., TZ, A.P.; Literature search – D.N., E.L., C.H., M.K., TZ, A.P.; Writing – D.N., B.K., LD., E.L., TZ, A.P.; Critical review – D.N., B.K., LD., E.L., M.P., C.H., A.A., M.K., TZ, A.P.

References

1. Schühlen H, Kastrati A, Dirschinger J, Hausleiter J, Elezi S, Wehinger A, et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 1998; 98: 104-11.
2. Kirtane AJ, Stone GW. How to minimize stent thrombosis. Circulation 2011; 124: 1283-7.
3. Lee CW, Park DW, Lee BK, Kim YH, Hong MK, Kim JJ, et al. Predictors of restenosis after placement of drug-eluting stents in one or more coronary arteries. Am J Cardiol 2006; 97: 506-11.
4. D’Ascenzo F, Bolliati M, Clementi F, Castagno D, Lagerqvist B, de la Torre Hernandez JM, et al. Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol 2013; 167: 575-84.
5. Suh J, Park DW, Lee JY, Jung IH, Lee SW, Kim YH, et al. The relationship and threshold of stent length with regard to risk of stent thrombosis after drug-eluting stent implantation. JACC Cardiovasc Interv 2010; 3: 383-9.
6. Guzman LA, Mick MJ, Arnold AM, Forudi F, Whitlow PL. Role of intimal hyperplasia and arterial remodeling after balloon angioplasty: an experimental study in the atherosclerotic rabbit model. Arterioscler Thromb Vasc Biol 1996; 16: 479-87.
7. Taniwaki M, Stefanini GG, Silber S, Richardt G, Vranckx P, Serruys PW, et al.; RESOLUTE All-Comers Investigators. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention). J Am Coll Cardiol 2014; 63: 1617-25.
8. Siontis GC, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Pérez-Vizcayno MJ, et al. Percutaneous coronary intervention strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet 2015; 386: 655-64.
9. Habara S, Kadota K, Shimada T, Ohya M, Amano H, Izawa Y, et al. Late Restenosis After Paclitaxel-Coated Balloon Angioplasty Occurs in Patients With Drug-Eluting Stent Restenosis. J Am Coll Cardiol 2015; 66: 14-22.
10. Wöhrle J, Zadura M, Möbius-Winkler S, Leschke M, Opitz C, Ahmed W, et al. SeQuent Please World Wide Registry: clinical results of Se-Quent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. J Am Coll Cardiol 2012; 60: 1733-8.
11. Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, et al., 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541-619.
12. Loh JP, Waksman R. Paclitaxel drug-coated balloons: a review of current status and emerging applications in native coronary artery de novo lesions. JACC Cardiovasc Interv 2012; 5: 1001-12.
13. Altman DG. Practical statistics for medical research. Chapman and Hall, London; 1991.
14. Holmes DR Jr, Kereiakes DJ, Garg S, Serruys PW, Dehmer GJ, Ellis SG, et al. Stent thrombosis. J Am Coll Cardiol 2010; 56: 1357-65.
15. Assadi-Schmidt A, Mohring A, Liebsch E, Dannenberg L, Achilles A, Pöhl M, et al. SeQuent Please vs. Pantera Lux drug coated balloon angioplasty in real life: Results from the Düsseldorf DCB registry. Int J Cardiol 2017; 231: 68-72.
16. Grundeck MJ, Ishibashi Y, Généreux P, LaSalle L, Iqbal J, Wykrzykowska JJ, et al. Inter-core lab variability in analyzing quantitative coronary angiography for bifurcation lesions: a post-hoc analysis of a randomized trial. JACC Cardiovasc Interv 2015; 8: 305-14.
17. Brunetti ND, Delli Carri F, Ruggiero MA, Cuculo A, Ruggiero A, Ziccardi L, et al. Comparative cath-lab assessment of coronary stenosis by radiology technician, junior and senior interventional cardiologist in patients treated with coronary angioplasty. Interv Med Appl Sci 2014; 6: 26-30.